Myriad Genetics (MYGN) Free Cash Flow (2009 - 2026)

Myriad Genetics (MYGN) has reported Free Cash Flow for 18 consecutive years, with -$21.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow rose 2.31% year-over-year to -$21.1 million; the TTM figure through Mar 2026 stood at -$13.3 million (up 56.96% YoY), while the FY2025 annual figure was -$13.8 million, up 50.18% from the prior year.
• Free Cash Flow fell to -$21.1 million in Q1 2026 per MYGN's latest filing, from $5.9 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $22.6 million in Q2 2023 and bottomed at -$56.7 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$19.1 million across 5 years, with a median of -$20.5 million in 2022.
• Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 181.61% — and 2025, when it jumped 439.29%.
• Myriad Genetics' Free Cash Flow stood at -$21.9 million in 2022, then sank by 116.89% to -$47.5 million in 2023, then soared by 106.32% to $3.0 million in 2024, then soared by 96.67% to $5.9 million in 2025, then tumbled by 457.63% to -$21.1 million in 2026.
• Business Quant data shows MYGN's Free Cash Flow at -$21.1 million in Q1 2026, $5.9 million in Q4 2025, and $9.5 million in Q3 2025.